Anti-CD20 therapies for multiple sclerosis: current status and future perspectives M Margoni, P Preziosa, M Filippi, MA Rocca Journal of Neurology 269 (3), 1316-1334, 2022 | 71 | 2022 |
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: a multicentre, Italian, retrospective, observational study D Baroncini, M Zaffaroni, L Moiola, L Lorefice, G Fenu, P Iaffaldano, ... Multiple Sclerosis Journal 25 (3), 399-407, 2019 | 49 | 2019 |
Ketogenic diet in migraine treatment: a brief but ancient history F Maggioni, M Margoni, G Zanchin Cephalalgia 31 (10), 1150-1151, 2011 | 41 | 2011 |
Selective cerebellar atrophy associates with depression and fatigue in the early phases of relapse-onset multiple sclerosis A Lazzarotto, M Margoni, S Franciotta, S Zywicki, A Riccardi, D Poggiali, ... The Cerebellum 19 (2), 192-200, 2020 | 36 | 2020 |
No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab M Margoni, F Rinaldi, A Riccardi, S Franciotta, P Perini, P Gallo Journal of Neurology 267, 100-105, 2020 | 36 | 2020 |
Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis A Favaretto, A Lazzarotto, A Riccardi, S Pravato, M Margoni, F Causin, ... PloS one 12 (10), e0185626, 2017 | 26 | 2017 |
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis A Favaretto, A Lazzarotto, M Margoni, D Poggiali, P Gallo Multiple sclerosis and demyelinating disorders 3, 1-10, 2018 | 25 | 2018 |
Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD M Nosadini, M Eyre, T Giacomini, M Valeriani, M Della Corte, AD Praticò, ... Neurology: Neuroimmunology & Neuroinflammation 10 (1), e200065, 2022 | 18 | 2022 |
Therapy of pediatric-onset multiple sclerosis: state of the art, challenges, and opportunities M Margoni, F Rinaldi, P Perini, P Gallo Frontiers in Neurology 12, 676095, 2021 | 18 | 2021 |
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex M Margoni, M Gueye, A Meani, E Pagani, L Moiola, P Preziosa, M Filippi, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (3), 181-188, 2023 | 17 | 2023 |
A new Italian family with HTRA1 mutation associated with autosomal-dominant variant of CARASIL: are we pointing towards a disease spectrum? S Favaretto, M Margoni, L Salviati, L Pianese, R Manara, C Baracchini Journal of the Neurological Sciences 396, 108-111, 2019 | 16 | 2019 |
Monitoring progressive multiple sclerosis with novel imaging techniques M Petracca, M Margoni, G Bommarito, M Inglese Neurology and therapy 7, 265-285, 2018 | 16 | 2018 |
Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study M Margoni, E Pagani, A Meani, L Storelli, S Mesaros, J Drulovic, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (7), 741-752, 2022 | 15 | 2022 |
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis D Landi, F Bovis, A Grimaldi, PO Annovazzi, A Bertolotto, A Bianchi, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (12), 1306-1316, 2022 | 14 | 2022 |
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis M Margoni, F Rinaldi, S Miante, S Franciotta, P Perini, P Gallo Multiple Sclerosis Journal–Experimental, Translational and Clinical 5 (3 …, 2019 | 14 | 2019 |
Axonal water fraction as marker of white matter injury in primary‐progressive multiple sclerosis: A longitudinal study M Margoni, M Petracca, S Schiavi, M Fabian, A Miller, FD Lublin, ... European Journal of Neurology 26 (8), 1068-1074, 2019 | 13 | 2019 |
Retinal hyperreflecting foci associate with cortical pathology in multiple sclerosis M Pengo, S Miante, S Franciotta, M Ponzano, T Torresin, F Bovis, ... Neurology: Neuroimmunology & Neuroinflammation 9 (4), e1180, 2022 | 11 | 2022 |
Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis A Fiore, P Preziosa, N Tedone, M Margoni, C Vizzino, D Mistri, M Gueye, ... Molecular Psychiatry 28 (4), 1770-1782, 2023 | 10 | 2023 |
Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, Mri, and fluid biomarkers M Margoni, P Preziosa, P Tortorella, M Filippi, MA Rocca Neurotherapeutics 19 (4), 1216-1228, 2022 | 10 | 2022 |
Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis M Margoni, P Preziosa, MA Rocca, M Filippi Translational Psychiatry 13 (1), 264, 2023 | 9 | 2023 |